Niosomes encapsulating paclitaxel for oral bioavailability enhancement: Preparation, characterization, pharmacokinetics and biodistribution

Journal of Microencapsulation

Volumn 30, Issue 8, 2013, Pages 796-804

  Sezgin Bayindir, Zerrin ^a   Onay Besikci, Arzu ^a   Vural, Nilufer ^a   Yuksel, Nilufer ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Cancer; Oral delivery; Paclitaxel; Pharmacokinetics; Surfactants

Indexed keywords

BILE SALT; CARBOMER; CARBOPOL 971P; CARBOPOL 974P; CHOLESTEROL; DEOXYCHOLATE SODIUM; DICETYL PHOSPHATE; HYDROXYPROPYLMETHYLCELLULOSE; NIOSOME; PACLITAXEL; SODIUM CHLORIDE; SORBITAN PALMITATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; ENCAPSULATION; INTESTINE CARCINOMA; LIVER CELL CARCINOMA; MATERIAL COATING; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; SUSPENSION; SUSTAINED DRUG RELEASE;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HEXOSES; MALE; PACLITAXEL; RATS; RATS, WISTAR;

EID: 84886730364     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.788088     Document Type: Article

References (51)

1. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 2008;9:740-7
2. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm, 2005;290:155-9
3. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol, 1985;37:237-42
4. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 2010;99:2049-60
5. Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm, 2004;280:221-7
6. Cortesi R, Esposito E, Corradini F, Sivieri E, Drechsler M, Rossi A, Scatturin A, Menegatti E. Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. Int J Pharm, 2007;339:52-60
7. Cosco D, Paolino D, Muzzalupo R, Celia C, Citraro R, Caponio D, Picci N, Fresta M. Novel PEG-coated niosomes based on bolasurfactant as drug carriers for 5-fluorouracil. Biomed Microdevices, 2009;11:1115-25
8. Desai TR, Finlay WH. Nebulization of niosomal all-trans-retinoic acid: An inexpensive alternative to conventional liposomes. Int J Pharm, 2002;241:311-17
9. Domb AJ, Tabata Y, Ravi Kumar MNV, Farber S. 2007. Nanoparticles for pharmaceutical applications. In: Feng SS, Lee PPS, Win KY, eds. Nanoparticles of biodegradable polymers for cancer chemotherapy. Stevenson Ranch, CA: American Scientific, pp. 257-70
10. Dong Y, Feng SS. Nanoparticles of poly(D, L-lactide)/methoxy poly(ethylene glycol)-poly(D, L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A, 2006;78:12-19
11. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Cont Rel, 1990;11:205-14
12. Gianasi E, Cociancich F, Uchegbu IF, Florence AT, Duncan R. Pharmaceutical and biological characterisation of a doxorubicinpolymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. Int J Pharm, 1997;148:139-48
13. Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral paclitaxel (Paxoral plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer, 2006;95:794-800
14. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Coll Surf B Biointer, 2006;50:97-103
15. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech, 2009;10:1186-92
16. Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvantcarrier system for oral genetic immunization against hepatitis B. Immunol Lett, 2005;101:41-9
17. Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol, 2005;59:325-34
18. Kim S, Kim JY, Huh KM, Acharya G, Park K. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Cont Rel, 2008;132:222-9
19. Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathot RA, Rosing H, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol, 2003;14:197-204
20. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol, 2002;20:4508-16
21. Li X, Choi JS. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm, 2007;337: 188-93.
22. Luciani A, Olivier JC, Clement O, Siauve N, Brillet PY, Bessoud B, Gazeau F, Uchegbu IF, Kahn E, Frija G, et al. Glucose receptor MR imaging of tumors: Study in mice with PEGylated paramagnetic niosomes. J Radiol, 2004;231:135-42
23. Malingre MM, Terwogt JM, Beijnen JH, Rosing H Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol, 2000;18:2468-75
24. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of aciclovir from nano-liposomes and nano-niosomes: An in vitro study. Int J Nanomed, 2007;2:213-25
25. Muramatsu M, Kanada K, Nishida A, Ouchi K, Saito N, Yoshida M, Shimoaka A, Ozeki T, Yuasa H, Kanaya Y. Application of Carbopol to controlled release preparations I. Carbopol as a novel coating material. Int J Pharm, 2000;199:77-83
26. Naresh RA, Udupa N, Umadevi P. Niosomal plumbagin with reduced toxicity and improved anticancer activity in Balb/c Mice. J Pharm Pharmacol, 1996;48:1128-32
27. Nasr M, Mansour S, Mortada ND, Elshamy AA. Vesicular aceclofenac systems: A comparative study between liposomes and niosomes. J Microencap, 2008;25:499-512
28. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm, 2009;71:310-17
29. Ozeki T, Yuasa H, Okada H. Controlled release of drug via methylcellulose-carboxyvinylpolymer interpolymer complex solid dispersion. AAPS PharmSciTech, 2005;6:E231-6
30. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm, 1998; 172:1-15
31. Pang KS. Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos, 2003;31:1507-19
32. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm, 2008;353: 233-42
33. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 2007;328:130-41
34. Parmentier J, Becker MM, Heintz U, Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastrointestinal fluids. Int J Pharm, 2011;405:210-17
35. Parthasarathi G, Udupa N, Parameshwaraiah N, Pillai GK. Altered biological distribution of decreased neuromuscular toxicity of niosome encapsulated vincristine. Ind J Exp Bio, 1996;34: 124-30
36. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res, 2006;23:1243-50
37. Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. AAPS PharmSciTech, 2012;13:826-35
38. Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: Effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci, 2006;95:1873-87
39. Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. Cancer Chem Pharmacol, 2009;64:87-94
40. Singla AK, Garg A, Aggarwal A. Paclitaxel and its formulations. Int J Pharm, 2002;235:179-92
41. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Cont Rel, 2003;86:235-42
42. Uchegbu IF, Duncan R. Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): Effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm, 1997; 155:7-17
43. Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Del, 2003;10:251-62
44. Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH. Novel paclitaxel formulations for oral application: A phase I pharmacokinetic study in patients with solid tumours. Cancer Chem Pharmacol, 2007;60:635-42
45. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, et al. A novel selfmicroemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer, 2006;95:729-34
46. Venkatesan N, Vyas SP. Polymer-coated vesicles: Development and characterization. Drug Del, 1998;5:251-5
47. Werle M, Makhlof A, Takeuchi H. Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem Pharm Bull, 2010;58:432-4
48. Yang H, Deng A, Zhang J, Wang J, Lu B. Preparation, characterization and anticancer therapeutic efficacy of cisplatin-loaded niosomes. J Microencapsul, 2013;30(3):237-44
49. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Cont Rel, 2007a;120:169-77
50. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm, 2007b;338:317-26
51. Zhang Z, Feng SS. Self-assembled nanoparticles of poly(lactide)-Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm, 2006;324: 191-8.